Helomics Predictive Oncology Announces $4.1M Direct Offering On Thursday, Predictive Oncology closed another direct offering initiated earlier in the week, raising $2.2 million. Predictive Oncology Prices $2.2M Direct Offering The company has reached agreements with investors for a direct offering of 2.2 million shares at $1 per share, for gross proceeds of about $2.2 million. Predictive Oncology Prices $3.2M Public Offering The company operates three subsidiaries including Helomics, which provides tumor-analysis services for treatment personalization and new drug development. Helomics Inks Separate Pacts With UPMC, Interpace Dx for AI-Driven Oncology Decision Making The groups will use Helomics' artificial intelligence-based platform to develop tools to provide predictive therapeutic recommendations for ovarian and thyroid cancers. Helomics, ChemImage Partner on Prostate Cancer Monitoring Tech Development Through the deal, Helomics aims to build a predictive model of prostate cancer drug response based on a combination of genomic and spectroscopy data. Jun 14, 2019 People in the News: Thomas Schinecker, Amelia Warner, Bartu Ahiska, More Mar 21, 2019 Viome, Helomics Form Microbiome Analysis Partnership Aug 17, 2018 New Products Posted to GenomeWeb: Helomics, Empirical Bioscience, IncellDx, More Jun 29, 2018 Precision Therapeutics, Helomics Ink Merger Agreement Apr 23, 2018 Precision Therapeutics to Acquire Remaining Helomics Shares Dec 20, 2017 Helomics Inks Service Agreement for Ariel Precision Medicine Pancreatic Disease Assay Dec 20, 2017 Skyline Medical to Acquire Up to 25 Percent of Helomics Nov 1, 2017 Skyline Medical, Helomics Collaborate to Develop Personalized Cancer Dx Sep 19, 2017 Indivumed, Helomics Form Cancer Research Services Partnership Jan 12, 2017 Helomics, MDNA Partner on Diagnostics Dec 21, 2016 Helomics Completes Restructuring to Clinical CRO Nov 29, 2016 Med BioGene, Helomics Revise Licensing Agreement Feb 12, 2016 Helomics Continues Research Market Shift With Two New Components for Live Cell Platform Premium Mar 26, 2015 Helomics Joins UK Consortium to Support Cancer Dx, Therapeutics Development Mar 11, 2015 Helomics, Prime Health Services Ink Tumor Profiling Deal Jan 27, 2015 Helomics Reinvents Itself, Targets Personalized Healthcare Space with Omics Assets Premium Nov 12, 2014 Precision Therapeutics Renames Itself Helomics, Nabs $60M Investment Aug 15, 2014 Med BioGene Poised to take Precision Therapeutics to Arbitration over Milestone Payment Mar 24, 2014 Precision Therapeutics CLIA-Certified to Offer Med BioGene's GeneFx Lung Assay Jan 28, 2014 Precision Therapeutics, Partners Validate Almac's ColDx Colorectal Cancer Test ahead of US Launch Premium Load More Breaking News Verily Awarded CDC Contract for Wastewater Surveillance Genomic Health to Pay $32.5M to Resolve Cancer Test False Claims Allegations by DOJ Vela Diagnostics Inks Japan Distribution Agreement for HIV-1 Drug Resistance Tests Coronary Artery Calcification Contributors, Potential Drug Targets Found in Cross-Ancestry GWAS Max Planck Team Uses Spatial Single-Cell Proteomics Method to Analyze Hepatocyte Heterogeneity The Scan Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants. Small Study of Gene Editing to Treat Sickle Cell Disease In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms. Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema. Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.